EMUC23: GU cancer game-changers for 2023
September 14, 2023Read moreA collaborative approach to reviewing trials prevents tunnel vision Collaborative efforts are required to drive game-changing advancements in medical...
00
Adverse events: Cornerstone for safer pathways?
August 14, 2023Read moreLearning points from morbidity and mortality Adverse events can positively transform new approaches in patient management. How? By applying...
Synergy of specialties at EMUC23: Why MDTs are paramount to optimal patient care
June 7, 2023Read moreThroughout the years, the European Multidisciplinary Congress on Urological Cancers (EMUC) has garnered a loyal following and a steady growth...
AI opportunities in GU Cancers
November 12, 2022Read moreLooking to the future, Prof. Arnulf Stenzl (DE), Prof. Alberto Briganti (IT) and Dr. Bob Schijvenaars (NL) chaired the...
New trial results for PEACE-1, OpeRa, and adjuvant therapies in high-risk RCC
November 12, 2022Read moreA selection of new trial results were shared and discussed in Plenary Session 5 on day three of EMUC22....
Plenary Session 3 report: New strategies in BCa
November 11, 2022Read moreAfter a day full of supplementary meetings like ESUI22 and the YAU’s Autumn Meeting, day two of EMUC22 saw...
Diagnosing PCa – what’s the best option?
November 11, 2022Read moreThe objective of the 14th European Multidisciplinary Congress on Urological Cancers is to work together to achieve the best...
What’s new in GU Pathology and WHO classification?
November 10, 2022Read moreThe Uropathology Symposium (ESUP) delivered the latest updates on the WHO classification of genito-urinary tract tumours for 2022, and...
ESUI22: Examining the near future of imaging
November 10, 2022Read moreThe 10th Meeting of the EAU Section of Urological Imaging got off to a good start on Thursday, 10 November,...
